EP3917507A4 - Administration de cannabinoïdes par infiltration tumescente - Google Patents

Administration de cannabinoïdes par infiltration tumescente Download PDF

Info

Publication number
EP3917507A4
EP3917507A4 EP20747957.7A EP20747957A EP3917507A4 EP 3917507 A4 EP3917507 A4 EP 3917507A4 EP 20747957 A EP20747957 A EP 20747957A EP 3917507 A4 EP3917507 A4 EP 3917507A4
Authority
EP
European Patent Office
Prior art keywords
cannabinoids
drug delivery
tumescent infiltration
infiltration drug
tumescent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20747957.7A
Other languages
German (de)
English (en)
Other versions
EP3917507A1 (fr
Inventor
Jeffrey Alan Klein
Paytra Alan Klein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hk Tumescent Pharma
Original Assignee
HK Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/264,440 external-priority patent/US11241412B2/en
Application filed by HK Pharma filed Critical HK Pharma
Publication of EP3917507A1 publication Critical patent/EP3917507A1/fr
Publication of EP3917507A4 publication Critical patent/EP3917507A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP20747957.7A 2019-01-31 2020-01-30 Administration de cannabinoïdes par infiltration tumescente Pending EP3917507A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16/264,440 US11241412B2 (en) 2015-10-12 2019-01-31 Tumescent infiltration drug delivery of cannabinoids
PCT/US2020/015963 WO2020160328A1 (fr) 2019-01-31 2020-01-30 Administration de cannabinoïdes par infiltration tumescente

Publications (2)

Publication Number Publication Date
EP3917507A1 EP3917507A1 (fr) 2021-12-08
EP3917507A4 true EP3917507A4 (fr) 2022-11-09

Family

ID=71840463

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20747957.7A Pending EP3917507A4 (fr) 2019-01-31 2020-01-30 Administration de cannabinoïdes par infiltration tumescente

Country Status (2)

Country Link
EP (1) EP3917507A4 (fr)
WO (1) WO2020160328A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10493024B2 (en) 2015-10-12 2019-12-03 Hk Tumescent Pharma Corporation Tumescent infiltration drug delivery of high subcutaneous drug concentrations with prolonged local and systemic effects and minimal local or systemic toxicity

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011066577A1 (fr) * 2009-11-30 2011-06-03 Jeffrey Alan Klein Solution antibiotique tumescente
US20130116223A1 (en) * 2009-03-02 2013-05-09 Doris Hexsel Medicinal cosmetic lipoatrophy
WO2018081740A1 (fr) * 2016-10-28 2018-05-03 The Regents Of The University Of California Injection tumescente d'antibiotiques destinée au traitement d'infections chroniques de la peau et des tissus mous

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3066426A1 (fr) * 2008-01-09 2009-07-16 Charleston Laboratories, Inc. Compositions pharmaceutiques renfermant un antiemetique et un analgesique opioide
US8808734B2 (en) * 2011-07-11 2014-08-19 Full Spectrum Laboratories Limited Cannabinoid formulations
US10493024B2 (en) * 2015-10-12 2019-12-03 Hk Tumescent Pharma Corporation Tumescent infiltration drug delivery of high subcutaneous drug concentrations with prolonged local and systemic effects and minimal local or systemic toxicity

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130116223A1 (en) * 2009-03-02 2013-05-09 Doris Hexsel Medicinal cosmetic lipoatrophy
WO2011066577A1 (fr) * 2009-11-30 2011-06-03 Jeffrey Alan Klein Solution antibiotique tumescente
WO2018081740A1 (fr) * 2016-10-28 2018-05-03 The Regents Of The University Of California Injection tumescente d'antibiotiques destinée au traitement d'infections chroniques de la peau et des tissus mous

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GREGG J M ET AL: "Cardiovascular effects of cannabinol during oral surgery", ANESTHESIA AND ANALGESIA 1976, vol. 55, no. 2, 1976, pages 203 - 213, XP009539446, ISSN: 0003-2999 *
NEWTON S C ET AL: "In vitro effects of psychoactive and non-psychoactive cannabinoids on immature rat sertoli cell function", LIFE SCIENCE, PERGAMON PRESS, OXFORD, GB, vol. 53, no. 18, 1 January 1993 (1993-01-01), pages 1429 - 1437, XP023740434, ISSN: 0024-3205, [retrieved on 19930101], DOI: 10.1016/0024-3205(93)90585-Q *
See also references of WO2020160328A1 *

Also Published As

Publication number Publication date
EP3917507A1 (fr) 2021-12-08
WO2020160328A1 (fr) 2020-08-06

Similar Documents

Publication Publication Date Title
EP4045024A4 (fr) Administration transdermique de cannabidiol
EP3538078A4 (fr) Formulations pour administration efficace de cannabinoïdes
EP3518981A4 (fr) Administration d'arn thérapeutiques par le biais de microvésicules à arrdc1
EP3548005A4 (fr) Exosomes destinés à l'administration d'agents thérapeutiques
EP3941561A4 (fr) Système d'administration par voie nasale de médicament
EP3941630A4 (fr) Distribution précise de constituants dans des fluides
EP3731846A4 (fr) Systèmes d'administration de médicament pour le traitement d'infections
EP4081169A4 (fr) Dispositifs médicaux pour distribution de fluide
EP3413909A4 (fr) Administration sous-cutanée d'adénovirus à double ciblage
EP3934717A4 (fr) Administration le fluide d'une seringue
EP3664885A4 (fr) Système d'administration transdermique de médicament
EP4007564A4 (fr) Administration intracrânienne d'une solution médicamenteuse
EP3399974A4 (fr) Administration de cannabinoïdes par l'intermédiaire d'aliments
EP3777893A4 (fr) Utilisation d'un composé de bis-iminobiotine pour des fins d'administration de médicament
EP3888726A4 (fr) Pompe de distribution de liquide
EP3917507A4 (fr) Administration de cannabinoïdes par infiltration tumescente
EP3720422A4 (fr) Système liposomal pour l'administration de médicaments
EP4081206A4 (fr) Préparation de cannabichromène et de cannabinoïdes apparentés
EP3596175A4 (fr) Nanoparticules pour l'administration d'agents chimiopréventifs
EP4049698A4 (fr) Dispositif d'administration d'agent médicamenteux
EP4006057A4 (fr) Complexe pour administration intracellulaire de molécules
EP3982929A4 (fr) Composition d'administration de médicament à base d'hydrogel
EP3958972A4 (fr) Médicament thérapeutique pour la dyskinésie
EP3836866A4 (fr) Systèmes d'administration entérique d'agents thérapeutiques
EP3888693A4 (fr) Système d'administration de médicament utilisant une solution

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210826

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40066815

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20221010

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 23/02 20060101ALI20221004BHEP

Ipc: A61K 31/522 20060101ALI20221004BHEP

Ipc: A61K 31/352 20060101ALI20221004BHEP

Ipc: A61K 31/137 20060101AFI20221004BHEP

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: HK TUMESCENT PHARMA

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20240731